4.6 Article

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Related references

Note: Only part of the references are listed.
Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Editorial Material Oncology

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Wenhua Liang et al.

LANCET ONCOLOGY (2020)

Editorial Material Medicine, General & Internal

Oncology Practice During the COVID-19 Pandemic

Deborah Schrag et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Multidisciplinary Sciences

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Abishek Chandrashekar et al.

SCIENCE (2020)

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Letter Medicine, General & Internal

Who should be prioritised for COVID-19 vaccines?

Zaki Hassan-Smith et al.

LANCET (2020)

Article Multidisciplinary Sciences

Age-specific differences in the dynamics of protective immunity to influenza

Sylvia Ranjeva et al.

NATURE COMMUNICATIONS (2019)

Review Chemistry, Medicinal

Immune Senescence and Vaccination in the Elderly

Pierre Olivier Lang et al.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)

Article Immunology

IFN-α subtypes differentially affect human T cell motility

GR Foster et al.

JOURNAL OF IMMUNOLOGY (2004)